These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 38010137)

  • 1. C-type lectin-like receptor-2 (CLEC-2) is a key regulator of kappa-carrageenan-induced tail thrombosis model in mice.
    Yokomori R; Shirai T; Tsukiji N; Oishi S; Sasaki T; Takano K; Suzuki-Inoue K
    Platelets; 2023 Dec; 34(1):2281941. PubMed ID: 38010137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galectin-9 activates platelet ITAM receptors glycoprotein VI and C-type lectin-like receptor-2.
    Zhi Z; Jooss NJ; Sun Y; Colicchia M; Slater A; Moran LA; Cheung HYF; Di Y; Rayes J; Poulter NS; Watson SP; Iqbal AJ
    J Thromb Haemost; 2022 Apr; 20(4):936-950. PubMed ID: 34936188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2.
    Suzuki-Inoue K; Fuller GL; García A; Eble JA; Pöhlmann S; Inoue O; Gartner TK; Hughan SC; Pearce AC; Laing GD; Theakston RD; Schweighoffer E; Zitzmann N; Morita T; Tybulewicz VL; Ozaki Y; Watson SP
    Blood; 2006 Jan; 107(2):542-9. PubMed ID: 16174766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significant Hypo-Responsiveness to GPVI and CLEC-2 Agonists in Pre-Term and Full-Term Neonatal Platelets and following Immune Thrombocytopenia.
    Hardy AT; Palma-Barqueros V; Watson SK; Malcor JD; Eble JA; Gardiner EE; Blanco JE; Guijarro-Campillo R; Delgado JL; Lozano ML; Teruel-Montoya R; Vicente V; Watson SP; Rivera J; Ferrer-Marín F
    Thromb Haemost; 2018 Jun; 118(6):1009-1020. PubMed ID: 29695020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets.
    Spalton JC; Mori J; Pollitt AY; Hughes CE; Eble JA; Watson SP
    J Thromb Haemost; 2009 Jul; 7(7):1192-9. PubMed ID: 19422460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Src but not Syk causes weak reversal of GPVI-mediated platelet aggregation measured by light transmission aggregometry.
    Cheung HYF; Moran LA; Sickmann A; Heemskerk JWM; Garcia Á; Watson SP
    Platelets; 2022 Nov; 33(8):1293-1300. PubMed ID: 35535424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorylation on Syk Y342 is important for both ITAM and hemITAM signaling in platelets.
    Kostyak JC; Mauri B; Dangelmaier C; Vari HR; Patel A; Wright M; Reddy H; Tsygankov AY; Kunapuli SP
    J Biol Chem; 2022 Aug; 298(8):102189. PubMed ID: 35753354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. G
    Badolia R; Inamdar V; Manne BK; Dangelmaier C; Eble JA; Kunapuli SP
    J Biol Chem; 2017 Sep; 292(35):14516-14531. PubMed ID: 28705934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RhoG protein regulates glycoprotein VI-Fc receptor γ-chain complex-mediated platelet activation and thrombus formation.
    Kim S; Dangelmaier C; Bhavanasi D; Meng S; Wang H; Goldfinger LE; Kunapuli SP
    J Biol Chem; 2013 Nov; 288(47):34230-34238. PubMed ID: 24106269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heme activates platelets and exacerbates rhabdomyolysis-induced acute kidney injury via CLEC-2 and GPVI/FcRγ.
    Oishi S; Tsukiji N; Otake S; Oishi N; Sasaki T; Shirai T; Yoshikawa Y; Takano K; Shinmori H; Inukai T; Kondo T; Suzuki-Inoue K
    Blood Adv; 2021 Apr; 5(7):2017-2026. PubMed ID: 33843987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct pathways regulate Syk protein activation downstream of immune tyrosine activation motif (ITAM) and hemITAM receptors in platelets.
    Manne BK; Badolia R; Dangelmaier C; Eble JA; Ellmeier W; Kahn M; Kunapuli SP
    J Biol Chem; 2015 May; 290(18):11557-68. PubMed ID: 25767114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of C-type lectin-like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides.
    Delierneux C; Donis N; Servais L; Wéra O; Lecut C; Vandereyken M; Musumeci L; Rahmouni S; Schneider J; Eble JA; Lancellotti P; Oury C
    J Thromb Haemost; 2017 May; 15(5):983-997. PubMed ID: 28296036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. G6b-B inhibits constitutive and agonist-induced signaling by glycoprotein VI and CLEC-2.
    Mori J; Pearce AC; Spalton JC; Grygielska B; Eble JA; Tomlinson MG; Senis YA; Watson SP
    J Biol Chem; 2008 Dec; 283(51):35419-27. PubMed ID: 18955485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dextran sulfate triggers platelet aggregation via direct activation of PEAR1.
    Vandenbriele C; Sun Y; Criel M; Cludts K; Van Kerckhoven S; Izzi B; Vanassche T; Verhamme P; Hoylaerts MF
    Platelets; 2016 Jun; 27(4):365-72. PubMed ID: 26619766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Akt and mitogen-activated protein kinase enhance C-type lectin-like receptor 2-mediated platelet activation by inhibition of glycogen synthase kinase 3α/β.
    Moroi AJ; Watson SP
    J Thromb Haemost; 2015 Jun; 13(6):1139-50. PubMed ID: 25858425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CEACAM2 negatively regulates hemi (ITAM-bearing) GPVI and CLEC-2 pathways and thrombus growth in vitro and in vivo.
    Alshahrani MM; Yang E; Yip J; Ghanem SS; Abdallah SL; deAngelis AM; O'Malley CJ; Moheimani F; Najjar SM; Jackson DE
    Blood; 2014 Oct; 124(15):2431-41. PubMed ID: 25085348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of glycoprotein VI (GPVI) and C-type lectin-like receptor-2 (CLEC-2) underlies platelet activation by diesel exhaust particles and other charged/hydrophobic ligands.
    Alshehri OM; Montague S; Watson S; Carter P; Sarker N; Manne BK; Miller JL; Herr AB; Pollitt AY; O'Callaghan CA; Kunapuli S; Arman M; Hughes CE; Watson SP
    Biochem J; 2015 Jun; 468(3):459-73. PubMed ID: 25849538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trivalent nanobody-based ligands mediate powerful activation of GPVI, CLEC-2, and PEAR1 in human platelets whereas FcγRIIA requires a tetravalent ligand.
    Martin EM; Clark JC; Montague SJ; Morán LA; Di Y; Bull LJ; Whittle L; Raka F; Buka RJ; Zafar I; Kardeby C; Slater A; Watson SP
    J Thromb Haemost; 2024 Jan; 22(1):271-285. PubMed ID: 37813196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LAT is required for tyrosine phosphorylation of phospholipase cgamma2 and platelet activation by the collagen receptor GPVI.
    Pasquet JM; Gross B; Quek L; Asazuma N; Zhang W; Sommers CL; Schweighoffer E; Tybulewicz V; Judd B; Lee JR; Koretzky G; Love PE; Samelson LE; Watson SP
    Mol Cell Biol; 1999 Dec; 19(12):8326-34. PubMed ID: 10567557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C-type lectin-like receptor-2 in platelets mediates ferric chloride-induced platelet activation and attenuates ferroptosis of endothelial cells.
    Tsukiji N; Yokomori R; Takusagawa K; Shirai T; Oishi S; Sasaki T; Takano K; Suzuki-Inoue K
    J Thromb Haemost; 2024 Jun; 22(6):1749-1757. PubMed ID: 38811291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.